Close Menu

NEW YORK (GenomeWeb) – Danaher today initiated its earning outlook for 2019, saying EPS is anticipated to be in the range of $4.02 to $4.12.

On a non-GAAP basis, EPS is expected to be in the range of $4.75 to $4.85, which assumes non-GAAP core revenue growth of about 4 percent. The Washington-based conglomerate, which owns Cepheid, Sciex, Beckman Coulter, and other life sciences and diagnostics companies, issued its guidance ahead of its annual investor and analyst meeting being held today.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.